Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters | Fierce Pharma
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Kåre Schultz forlænger kontrakt med Teva — MedWatch
Kåre Schultz får lønforhøjelse på 26 mio. kr. — MedWatch
Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Teva takes 2nd long-acting schizophrenia drug into phase 3
Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United States | Business Wire
Kåre Schultz får ikke opfyldt ønske om bestyrelsespost hos Teva — MedWatch
Teva indgår milliardforlig i opiodsag — MedWatch
Teva's Copaxone Successors Are Still Far From Success | Ctech
Teva takes 2nd long-acting schizophrenia drug into phase 3
Teva CEO Schultz took a big pay cut last year—but he bagged a contract extension, too | Fierce Pharma
Teva | Contract Pharma
Now That Teva Has Stabilized, Teva Stock Looks Undervalued | InvestorPlace
Business-overblik: Kåre Schultz har planlagt sit farvel til topjob i Teva
Kaare Schultz Net Worth (2023) | wallmine
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Kåre Schultz forlænger kontrakt med Teva — MedWatch
Nedtælling for Kåre Schultz: “Inden for de næste 12 måneder vil de finde min afløser”
Teva: Vil tålmodigheden blive belønnet? | Nordnet
Teva USA
Dansk topchef stopper i Teva før tid
Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Teva CEO Kåre Schultz discusses company's latest quarter and opioid settlement - YouTube
Teva USA
